Job description 

The Stagg lab is focused at identifying novel therapeutic targets in order to potentiate the activity of immune checkpoint blockade (ICB). Our pipeline is based on multi-omics analyses of human tumor samples, genetically engineered preclinical models and the development of nove monoclonal antibodies.  

The candidate will work to map human tumors’ adaptation to ICB and validate new therapeutic targets and develop/screen functional monoclonal antibodies against the targets. The candidate will be integrated in our international network of collaborators in world-leading cancer centers. 

Responsibilities 

This person will be responsible to:

• Lead independent research projects (drive projects forward, analyze & interpret data)  
• Thrive in a collaborative work environment; 
• Demonstrate excellent competency in written and verbal communications; 
• Abide to the highest standards of excellence and integrity. 

Qualifications

• Ph.D. in immunology, antibody engineering, molecular biology, or a related field. 
• Prior experience at developing and screening monoclonal antibodies and performing preclinical studies is desired.  

Competitive benefits 

• Full-time position, 35 hours per week
• Flexibility of the schedule and work from home possible
• 12 months contract, renewable
• Competitive salary
• Start date: as soon as possible

To apply

Interested candidates should e-mail their cover letter and curriculum vitae, including three references to: 

John.stagg@umontreal.ca

It is essential to attach your CV for your application to be considered.

Only successful candidates will be contacted for an interview.

The CRCHUM invites women, Aboriginals, visible minorities, ethnic minorities and people with disabilities to apply. The CRCHUM adopts a broad and inclusive definition of diversity that goes beyond applicable laws. 

The CRCHUM thus encourages all people, regardless of their characteristics, to apply. In accordance with Canadian immigration requirements, please note that priority will be given to Canadian citizens and permanent resident.